Literature DB >> 18454482

IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles.

Anil K Tyagi1, Theodore W Randolph, Aichun Dong, Kevin M Maloney, Carl Hitscherich, John F Carpenter.   

Abstract

This study investigated factors associated with vial filling with a positive displacement piston pump leading to formation of protein particles in a formulation of an IgG. We hypothesized that nanoparticles shed from the pump's solution-contact surfaces nucleated protein aggregation and particle formation. Vials of IgG formulation filled at a clinical manufacturing site contained a few visible particles and about 100,000 particles (1.5-3 microm) per mL. In laboratory studies with the same model (National Instruments FUS-10) of pump, pumping of 20 mg/mL IgG formulation resulted in about 300,000 particles (1.5-3 microm) per mL. Pumping of protein-free formulation resulted in 13,000 particles (1.5-15 microm) per mL. More than 99% of the particles were 0.25-0.95 microm in size. Mixing of protein-free pumped solution with an equal volume of 40 mg/mL IgG resulted in 300,000 particles (1.5-15 microm) per mL. Also, mixing IgG formulation with 30,000/mL stainless steel nanoparticles resulted in formation of 30,000 protein microparticles (1.5-15 microm) per mL. Infrared spectroscopy showed that secondary structure of IgG in microparticles formed by pumping or mixing with steel nanoparticles was minimally perturbed. Our results document that nanoparticles of foreign materials shed by pumps can serve as heterogeneous nuclei for formation of protein microparticles. (c) 2008 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18454482     DOI: 10.1002/jps.21419

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  27 in total

1.  The Coulter principle for analysis of subvisible particles in protein formulations.

Authors:  Matthew N Rhyner
Journal:  AAPS J       Date:  2010-12-14       Impact factor: 4.009

2.  Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Coronado, CA USA.

Authors:  Janice M Reichert; Nitya Jacob; Ashraf Amanullah
Journal:  MAbs       Date:  2009-05-20       Impact factor: 5.857

Review 3.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

4.  Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.

Authors:  Paolo Arosio; Simonetta Rima; Massimo Morbidelli
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

5.  Protein Adsorption and Layer Formation at the Stainless Steel-Solution Interface Mediates Shear-Induced Particle Formation for an IgG1 Monoclonal Antibody.

Authors:  Cavan K Kalonia; Frank Heinrich; Joseph E Curtis; Sid Raman; Maria A Miller; Steven D Hudson
Journal:  Mol Pharm       Date:  2018-02-20       Impact factor: 4.939

6.  A Flow-Cytometry-Based Approach to Facilitate Quantification, Size Estimation and Characterization of Sub-visible Particles in Protein Solutions.

Authors:  Christian Lubich; Mantas Malisauskas; Thomas Prenninger; Thomas Wurz; Peter Matthiessen; Peter L Turecek; Friedrich Scheiflinger; Birgit M Reipert
Journal:  Pharm Res       Date:  2015-03-19       Impact factor: 4.200

7.  Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies.

Authors:  Jared S Bee; David Chiu; Suzanne Sawicki; Jennifer L Stevenson; Koustuv Chatterjee; Erwin Freund; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

8.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.

Authors:  John F Carpenter; Theodore W Randolph; Wim Jiskoot; Daan J A Crommelin; C Russell Middaugh; Gerhard Winter; Ying-Xin Fan; Susan Kirshner; Daniela Verthelyi; Steven Kozlowski; Kathleen A Clouse; Patrick G Swann; Amy Rosenberg; Barry Cherney
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

Review 9.  Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

Authors:  Anna N Ilinskaya; Marina A Dobrovolskaia
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-07       Impact factor: 4.219

10.  Response of a concentrated monoclonal antibody formulation to high shear.

Authors:  Jared S Bee; Jennifer L Stevenson; Bhavya Mehta; Juraj Svitel; Joey Pollastrini; Robert Platz; Erwin Freund; John F Carpenter; Theodore W Randolph
Journal:  Biotechnol Bioeng       Date:  2009-08-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.